The ADVANCE trial

The Lancet

Volumn 371, Issue 9606, 2008, Pages 25-

  Fuchs, Flávio Danni ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; INDAPAMIDE; PERINDOPRIL; PLACEBO; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROL GROUP; DIABETIC PATIENT; DRUG SUBSTITUTION; HUMAN; LETTER; MEDICAL ETHICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

EID: 37449034407     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60059-8     Document Type: Letter

References (3)

1. Patel A., and ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
2. Anon. The sixth report of the Joint National Committee on prevention, evaluation and treatment of high blood pressure. Arch Intern Med 157 (1997) 2413-2446
3. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-259